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Abstract
Background: We have previously identified a locus on human chromosome 20q13.1, encompassing related genes
of postulated WFDC-type protease inhibitors and semen coagulum proteins. Three of the genes with WFDC motif
also coded for the Kunitz-type protease inhibitor motif. In this report, we have reinvestigated the locus for
homologous genes encoding Kunitz motif only. The identified genes have been analyzed with respect to structure,
expression and function.
Results: We identified three novel genes; SPINT3, SPINT4 and SPINT5, and the structure of their transcripts were
determined by sequencing of DNA generated by rapid amplification of cDNA ends. Each gene encodes a Kunitz
domain preceded by a typical signal peptide sequence, which indicates that the proteins of 7.6, 8.7, and 9.7 kDa
are secreted. Analysis of transcripts in 26 tissues showed that the genes predominantly are expressed in the
epididymis. The recombinantly produced proteins could not inhibit the amidolytic activity of trypsin, chymotrypsin,
plasmin, thrombin, coagulation factor Xa, elastase, urokinase and prostate specific antigen, whereas similarly made
bovine pancreatic trypsin inhibitor (BPTI) had the same bioactivity as the protein isolated from bovine pancreas.
Conclusions: The similar organization, chromosomal location and site of expression, suggests that the novel genes
are homologous with the genes of WFDC-type protease inhibitors and semen coagulum proteins, despite the lack
of similarity in primary structure of their protein products. Their restricted expression to the epididymis suggests
that they could be important for male reproduction. The recombinantly produced proteins are presumably
bioactive, as demonstrated with similarly made BPTI, but may have a narrower spectrum of inhibition, as indicated
by the lacking activity against eight proteases with differing specificity. Another possibility is that they have lost the
protease inhibiting properties, which is typical of Kunitz domains, in favor of hitherto unknown functions.
Background
The mammalian semen coagulum proteins are a hetero-
geneous collection of proteins secreted at very high con-
centration by the seminal vesicles. There are two
homologous semen coagulum proteins, denoted seme-
nogelin I (SEMG1) and semenogelin II (SEMG2), in
most primates [1-3]. Duplication of tandem repeats of
60 amino acid residues in both SEMG1 and SEMG2 is
responsible for most of the size heterogeneity of seme-
nogelin molecules in primates, but the frequent occur-
rence of premature stop codons is also a contributing
factor [1,4,5]. It has also been reported that the struc-
ture of semenogelin molecules can be affected by gene
conversion [6].
The murine seminal vesicles secrete six proteins, Svs1-
Svs6, at high concentration [7-9]. It has been shown that
the genes of Svs2-Svs6, and SEMG1 and SEMG2 are
homologous, in spite of lacking similarity between their
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explained by rapid evolution of single exon that codes
for most of the gene product. The homologous genes
are composed of three exons, the first of which encodes
the signal peptide and the very first residues of the
secreted protein, the second codes for the remainder of
the protein and also carries a few 3’ non-translated
nucleotides, whereas the third exon only has 3’ non-
translated nucleotides and holds the poly-adenylation
signal. Sequence comparison shows that the first and
last exons are conserved in these genes, whereas the sec-
ond exon is not [10]. Differing selection of splice accep-
tor sites and species unique repeat expansion have been
proposed to explain the diversity of the second exon
[10].
T h ep r o p o s e de v o l u t i o n a r ym e c h a n i s m ss u g g e s tt h a t
the seminal vesicle-transcribed genes might be related
to genes with similar organization that code for
secreted, but structurally very different proteins. This
hypothesis led to the discovery that the genes of the
elastase inhibitors elafin and secretory leukocyte pro-
tease inhibitor (SLPI), and the predominating seminal
vesicle-secreted proteins are homologous, in spite of
lacking similarity between their protein products [12].
Elafin and SLPI belong to the whey acidic protein
four-disulfide core (WFDC) family of small protease
inhibitors, which interacts with cognate proteases by
what is known as the standard mechanism, by which
the protease-binding loop of the inhibitors interacts
with the catalytic site of proteases in a similar way as
substrates [13].
With the advent of nucleotide sequences from the
Human Genome Project, it became possible to assign
the chromosomal location of genes in detail. Analysis of
the human semenogelin locus on chromosome 20q12-
13.1 showed that PI3, the gene of elafin, and SLPI are
flanking SEMG1 and SEMG2 and an extended analysis
of the chromosomal region identified 12 additional,
homologous genes encompassing WFDC motif [14,15].
Most of the WFDC genes and Svs2-Svs6 are conserved
at the homologous chromosomal region in the mouse,
which suggests that the semen coagulum proteins prob-
ably originate from a WFDC gene [16]. Many of the
WFDC genes are with certain specificity expressed in
the epididymis and display accelerated evolution, which
might indicate that they are of importance in male
reproduction [16].
Three of the novel genes with WFDC motifs, WFDC8,
SPINLW1,a n dWFDC6 also carry the motif of Kunitz-
type protease inhibitors [14]. Similar to the WFDC
domain, the conserved Kunitz domain is present in sev-
eral proteins that inhibit proteases by the standard
mechanism [13]. A well-known and much studied exam-
ple is the bovine pancreatic trypsin inhibitor (BPTI), also
known as aprotinin and until recently marketed as an
anti-bleeding drug under the name of Trasylol
®.K u n i t z
domains are also present in important protease inhibi-
tors, such as the tissue factor pathway inhibitor, which
regulates blood coagulation, and the light chain, also
known as bikunin, of the multifunctional inter-alpha
trypsin inhibitor [17-19].
We have in several previous studies, as outlined above,
demonstrated that many of the genes at the semenoge-
lin/WFDC locus are expressed in the male reproductive
tract and display accelerated evolution by a variety of
mechanisms. Most compelling are the findings suggest-
ing that a WFDC gene gave rise to the genes of the
semen coagulum proteins, as it also rises the question
whether there could be still more genes at the locus on
chromosome 20 that have gone through a similar meta-
morphosis. Our finding that the protease inhibitor locus
on chromosome 20 carries several genes that code for
inhibitors containing WFDC motifs only, while other
genes encode products containing both WFDC and
Kunitz motifs, raised the question as to whether there
also exists homologous genes encoding putative inhibi-
tors with Kunitz motifs alone. In this report, we have
searched the locus for novel genes encoding proteins
with Kunitz motifs. The identified genes have been ana-
lyzed with respect to structure, expression and function.
Results
Identification of three novel genes encoding Kunitz
domains
T h en u c l e o t i d es e q u e n c eo f1 . 8M bc e n t e r e do nt h e0 . 7
Mb WFDC locus on chromosome 20q13.1 was trans-
lated in 6 reading frames and screened for Kunitz
motifs. A total of six Kunitz motifs were detected, three
of which were associated with proteins containing both
Kunitz and WFDC motifs; the previously characterized
SPINLW1, WFDC8 and WFDC6 [14,20]. The human
WFDC locus consists of two subloci and the six genes
encoding Kunitz motifs are all located at the telomeric
sublocus (Figure 1). The first of the novel genes,
SPINT3, is located 34 kb on the telomeric side of
WFDC2 and 19 kb on the centromeric side of WFDC6.
We located SPINT4 and SPINT5 next to each other,
separated by 25 kb of intergenic DNA, with SPINT4
located 20 kb on the telomeric side of WFDC13 and
SPINT5 25 kb on the centromeric side of WFDC3.
Structure of transcripts
The nucleotide sequences of full-length transcripts of
the novel genes were obtained from overlapping
sequences generated by 3’,a n d5 ’ RACE with cDNA
from epididymis. The procedure yielded a single tran-
script for SPINT3, whereas two transcripts were asso-
ciated with SPINT4 and presumably three with SPINT5.
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Page 2 of 13All genes give rise to transcripts that encode a Kunitz
domain preceded by a signal peptide of 24 amino acid
residues, indicating that the protein products are
secreted. There are no signals for N-linked glycosylation
in the primary structures, which suggests that the pro-
teins are secreted without carbohydrate chains. Sizes of
exons and introns are given in Table 1.
The SPINT3 transcript of 476 bp [GenBank:
AY372172] terminates in a poly-A tail that is preceded
by an unconventional poly-adenylation signal, TATAAA,
which notably is identical to the canonical TATA-box
sequence in eukaryotic genes (Figure 2A). It gives rise to
a polypeptide of 89 amino acid residues that will be pro-
cessed to a secreted protein of 7.6 kDa. The gene is not
preceded by a conventional TATA-box, but there is an
A and T rich sequence, TAAAAT, 26 bp upstream to
the transcription initiation site.
The two SPINT4 transcripts are 380 [GenBank:
AY372173] and 514 [GenBank: AY372174] nucleotides
respectively. The difference between the transcripts is
found in the 3’ non-translated part, which in the smaller
transcript consists of 61 nucleotides that overlap with
those in the longer transcript of 194 nucleotides (Figure
2B). The conventional poly-adenylation signal,
AATAAA, used in the shorter transcript, is skipped in
the longer transcript for an unconventional poly-adeny-
lation signal, AATGAAA, located further downstream.
Both transcripts give rise to a polypeptide of 99 amino
acid residues, which is processed to a protein of 8.7
kDa, encompassing a Kunitz motif that is lacking the
fifth Cys of the consensus motif. Normally this would
yield a free thiol group in the third Cys, the binding
partner of the fifth Cys in the motif. However, there is
another Cys located upstream to the Kunitz motif that
potentially can form a disulphide with the third Cys of
the motif (Figure 2B). There is a TATA-like sequence,
TATAAC, preceding the gene by 25 bp.
It was more difficult to obtain RACE products from
SPINT5 than from the other two novel human Kunitz
genes, but two transcripts were generated each by 3’
RACE and 5’ RACE when run with nested primers. The
amplification problems suggests very low mRNA levels
and the structures of the transcripts, which include pre-
mature stop codon and extensively many 3’ non-trans-
lated exons, indicated that they might be spurious and
not fully processed. Therefore, in another set of experi-
ments, the Kunitz motif of Spint5 was identified in silico
in the mouse genome. Following RT-PCR detection of
the transcript in mouse testis, RACE, with testicular
cDNA and primers based on the genomic sequence,
yielded overlapping DNA fragments from which we
could determine the complete structure of mouse Spint5
[GenBank: AY542490]. The mouse transcript of 443 bp
is derived from four exons, two of which are located
upstream to the exon coding for the Kunitz domain
(Figure 3). In contrast to the human, the mouse tran-
script can be translated to yield a pre-protein of 105
amino acid residues that contains both a predicted sig-
nal peptide and the Kunitz domain. Removal of the sig-
nal peptide gives rise to a secreted protein of 9.1 kDa.
The human and mouse transcripts differ with respect to
the splicing of the second exon, which is only nine
nucleotides in the mouse and codes for three amino
WFDC2
WFDC6
WFDC8
WFDC10B
WFDC11
WFDC10A
WFDC9
WFDC13
WFDC3
SPINT4
SPINT5
SPINLW1
SPINT3
20 kb
Figure 1 Potential Kunitz inhibitors at the human WFDC locus. The two DNA-strands of the telomeric sublocus of the WFDC/Semenogelin
locus on human chromosome 20 are displayed as horizontal bars. The location of genes is indicated by thicker bars with arrow heads above or
below, which illustrate WFDC domains in white, Kunitz domains in black and signal peptide in grey.
Table 1 Exon and intron sizes
Gene Exons (bp) Introns (bp)
Human SPINT3 92; 384 2,688
Human SPINT4A 134; 178; 68 1,397; 1,571
Human SPINT4B 134; 178; 201 1,397; 1,571
Mouse Spint5 170; 9; 170; 94 571; 940; 810
Human SPINT5 142; 53; 169; 118 898; 547; 1,120
Human SPINT5 alt
5’
50 547
Human SPINT5 alt
3’
66; 236; 202; 179;
85
1,473; 8,037; 130; 1,917;
2,830
Exons were identified by sequence comparison between transcripts and the
reference genomic DNA in the Ensembl database (http://www.ensembl.org/
index.html). RACE products generating alternative 5’ and 3’ ends are indicated
with alt 5’ and alt 3’ respectively. Overlapping exon and intron sequences are
written with bold fonts.
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Page 3 of 13acid residues. The splice acceptor site of the mouse
transcript is structurally conserved in the human gen-
ome and, if used, it could generate a translation product
encompassing both a signal peptide and a secreted pro-
tein of 9.7 kDa with a Kunitz domain (Figure 3).
The RACE procedure also yielded products for alterna-
tive 5’ and 3’ ends of human SPINT5. The sequence of a
shorter 5’ RACE product overlaps with the human tran-
script that is orthologous with mouse Spint5, but starts
three nucleotides downstream of the splice acceptor site
of the second exon (Figure 3). This transcript could
potentially generate an intracellular Kunitz domain, as it
is lacking the coding information of the signal peptide.
The alternative 3’ end is longer and derived from 5 exons
located 3’ to the exon with the Kunitz motif.
Expression of transcripts in normal human tissues
Gene expression was analyzed by RT-PCR using RNA
from a panel of 26 tissue specimens that previously had
been screened for genes encoding WFDC domains [14].
Tissues that generated PCR products with the correct
size of spliced transcripts were taken to quantitative ana-
lysis using real time PCR. The housekeeping genes CSTB
and APRT, which were used for normalization of the
PCR data, generated transcripts with melting
temperatures of 80°C and 81.5°C and yielded Ct values in
the range of 23-25 and 25-27 respectively. SPINT3 and
SPINT4 gave rise to transcripts with melting tempera-
tures of 76.5°C and 74°C and with cDNA from epididy-
mis they generated Ct values that were similar or slightly
lower than those of CSTB,b u tf o rt h er e m a i n d e ro ft i s -
sues the Ct values were 32 or higher; in a few tissues
transcript was not even detectable. Different primer com-
binations were tested in order to measure the expression
of SPINT5,b u tad e t e c t a b l ea n ds p e c i f i cs i g n a lw a so n l y
obtained with a primer pair that primed in the Kunitz
domain and in the last exon of the transcript; it yielded a
Ct value of 35-36 in the epididymis. The efficacy of the
PCR reactions was analyzed by linear regression of Ct
values generated by serial dilution of epididymal cDNA
(Table 2). An efficacy of 2 was assumed for SPINT5,a s
low levels prohibited analysis of its transcript by linear
regression. Calculation of the relative expression shows
that the level of SPINT3 and SPINT4 transcripts in the
epididymis exceeds those in other tissues by more than
three orders of magnitude (Table 3).
Recombinant expression and functional analysis
Recombinant expression yielded proteins of around 27
kDa, which contain the Kunitz domains fused to vector
                 M  Q  L  Q  A  S  L  S  F  L  L  I  L  T  L  C  L  E  L  R  S  E  L  A  R
CTGGCTGAGTGGCACCATGCAGCTTCAGGCCTCTCTCTCGTTTCTCCTGATTCTCACTCTCTGCCTAGAGCTTCGATCAGAACTAGCACG
  D  T  I  K  D  L  L  P  N  V  C  A  F  P  M  E  K  G  P  C  Q  T  Y  M  T  R  W  F  F  N
AGACACTATCAAGGATCTCCTCCCAAATGTATGCGCTTTTCCTATGGAAAAGGGCCCTTGTCAAACCTACATGACGCGATGGTTTTTCAA
  F  E  T  G  E  C  E  L  F  A  Y  G  G  C  G  G  N  S  N  N  F  L  R  K  E  K  C  E  K  F
CTTTGAAACTGGTGAATGTGAGTTATTTGCTTACGGAGGCTGCGGAGGCAACAGCAACAACTTTTTGAGGAAAGAAAAATGTGAGAAATT
  C  K  F  T
CTGCAAGTTCACCTGATTTTCTAACAAGAACACAGCCCTCCATGGATTCGGGATTGCTCTGAGGGCCATAGAAGGCATTTGCGTGTGTGT
GTGTGTGTGAACAAGAGGTTCATTCCTCTACCCCCACATTTATTCTCCCTGATGTGCTCCTACAAGTGCTTCATCTCTGTGCCTGAAATT
CTATAAATGTTGCAATCATG
                    M  K  S  A  K  L  G  F  L  L  R  F  F  I  F  C  S  L  N  T  L  L  L  G
GCCTGCTGCTTGCTGCACCATGAAGTCTGCCAAGCTGGGATTTCTTCTAAGATTCTTCATCTTCTGCTCATTGAATACCCTGTTATTGGG
  G  V  N  K  I  A  E  K  I  C  G  D  L  K  D  P  C  K  L  D  M  N  F  G  S  C  Y  E  V  H
TGGTGTTAATAAAATTGCGGAGAAGATATGTGGAGACCTCAAAGATCCCTGCAAATTGGACATGAATTTTGGAAGCTGCTATGAAGTTCA
  F  R  Y  F  Y  N  R  T  S  K  R  C  E  T  F  V  F  S  G  C  N  G  N  L  N  N  F  K  L  K
CTTTAGATATTTCTACAACAGAACCTCCAAAAGATGTGAAACTTTTGTCTTCTCCGGCTGTAATGGCAACCTTAACAACTTCAAGCTTAA
  I  E  R  E  V  A  C  V  A  K  Y  K  P  P  R
AATAGAACGTGAAGTAGCCTGTGTTGCAAAATACAAACCACCGAGGTGAGAGGATGTGAACTCATGAAGTTGTCTGCTGCACCATCCGAA
ATAAAGACACAAGAAAATTCAGACTGATTTTGAAAATCTTTGTAATATTTCCATAATGCTTTAAGCTTCCATATGTTTGCTATTTTCCTG
ACCCTAGTTTTGCCTTTCCTGGAAATTAACTGTATGATCATTAGAATGAAAGAGTCTTTCTGTC
A
B
Figure 2 Structure of SPINT3 and SPINT4. The nucleotide sequences of transcripts are given with translation written above for (A) SPINT3 and
(B) SPINT4. The arrows indicate location of the predicted signal peptide cleavage sites. The two Cys in SPINT4, which might form an
unconventional disulphide bond, are boxed. The nucleotides present in the longer SPINT4 transcript, but not in the shorter, are italicized.
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Page 4 of 13encoded thioredoxin. Experiments with BPTI and BSTI,
which served as positive controls, yielded around 5 mg
of recombinant protein from 1 L of cultured bacteria
after purification on Ni-chelate column. The isolated
proteins were highly pure and appeared as single bands
on SDS-PAGE under both reducing and non-reducing
conditions. The isolated proteins were functionally
active, as demonstrated by the inhibition of trypsin,
plasmin and chymotrypsin by approximately equimolar
                                         M  A  G  P  G  I  R  L  A  L  W  L  L  T  F  A  M
AGTGTAGCTTGAGTCTCTCCTGTCTGCTGTCAGGAGCGCCATGGCGGGTCCAGGGATTCGCCTTGCCCTGTGGCTTCTAACGTTTGCCAT
                         |||||| | | |  ||||  |  |  | ||  || | || | || ||||| || |  ||  ||||
                         GCTGTCTGCAACATCATGAAGCCTGAATGGGCTCACTTTTCTCTATGGCTCCTCATCTTGTCCAT   Human
                                         M  K  P  E  W  A  H  F  S  L  W  L  L  I  L  S  M
  S  L  S  M  L  S  S  S  L  L  Y  P  A  G  V  R  S  Q  L  C  E  S  G  H  L  G  A  K  R  I
GTCCCTGTCAATGCTATCTAGTAGTTTGCTATATCCTGCAGGAGTCCGAAGTCAACTCTGCGAAAGCGGGCACCTTGGAGCGAAAAGAAT   Mouse
|   ||    |  |  ||  | |      ||| |||| ||  | || |||  ||  |  | ||||| || || |||||||  |||  |
GCTTCTCCACACACCTTCAGGGAAC---ATATTTCCTCCACAACTCAGAAAACAGTTACGTGAAAGTGGACATCTTGGAGTAAAACCAGA   Human
  L  L  H  T  P  S  G  N     I  F  P  P  Q  L  R  K  Q  L  R  E  S  G  H  L  G  V  K  P  E
TCATCATGGCTTCTGCTCTAACCACTTAATCTCCATGGTCTCAG
V  I  M  A  S  A  L  T  T ***
  I  C  N  Q  P  V  K  K  G  F  C  S  F  T  F  Y  R  Y  Y  F  N  P  E  S  A  L  C  E  S  F
AATATGCAACCAACCGGTAAAGAAGGGCTTCTGCAGCTTCACTTTCTACAGATACTACTTCAACCCAGAATCGGCCCTATGTGAGTCCTT   Mouse
|   |||||| | ||  | |||||||||  ||| |  |    |||   ||||| ||||| |||| |     |     |||||||| ||||
ATACTGCAACTATCCTCTGAAGAAGGGCACCTGTAATTCATATTTGACCAGATTCTACTACAACACTTTGACATTTTTATGTGAGCCCTT   Human
  Y  C  N  Y  P  L  K  K  G  T  C  N  S  Y  L  T  R  F  Y  Y  N  T  L  T  F  L  C  E  P  F
  I  F  T  G  C  G  G  N  R  N  N  F  K  T  K  Y  L  C  E  V  R  C  I  H  V  E 
CATCTTCACTGGCTGCGGGGGCAACAGAAACAACTTTAAAACTAAATACCTCTGTGAAGTCCGTTGCATTCACGTAGAG              Mouse
  |||||| |||||| || |||||||||||||||||||||   |||||  ||||||||      || |||   | | |
TGTCTTCAGTGGCTGTGGAGGCAACAGAAACAACTTTAAACAGAAATATTTCTGTGAAAAAATGTGTATTACTGAAAA               Human
  V  F  S  G  C  G  G  N  R  N  N  F  K  Q  K  Y  F  C  E  K  M  C  I  T  E  K
 K  D
AAGGACTAATCCAAACCCAGGAAAGCAGTAAGCGAAGGATGCAAGGAGCAGCGCCAGGCTCATATGCAGAGGGAATAAAGTCGAAACTTC   Mouse
TGAC
  D  Q  S  Q                                                                                 Human
GGACCAAAGTCAATAGGGCCTTAATATGACAGAAGGAGGAAACAAGGAAAAAGGAGTATGCTCTATGAAAAATCATGCCAAAGTTATTCT   SPINT5
GAGAAAATAAATTGGATTATTTCTAAAA
  F  F  Q  H  I  L  Q  M  T  S  L  Q  G  P  T  Y  P  C  N  A  S  V  L  S  P  P  A  P  R      Human
ATTCTTCCAACATATACTGCAAATGACCTCTCTGCAGGGACCAACCTATCCATGTAATGCATCAGTACTCAGCCCGCCTGCACCCAGGTG   SPINT5
AAATAAACAGCCACGTTGCTCACACAAAGCCTGTTTGGTGGTCTCTTCACACGGACGCGCATGAAATTTGGTGCCGTGACTCGGATTGGG   alt 3’
GGACCTCCCTTGGGAGATCAATCCCCTGTCCTCCTGCTCTTTGCTCCGTGAGAAAGATCCACCTATGACCTCAGGTCCTCAGACCGACCA
GCCCAAGAAACATCTCACCAATTTTAAATTGGAGACAAAGGAGACACGTTTTATCTGTGGACCCAAAACTCCGGCGCCGGTCGCAGACTA
GGGAAGGCAGCCTTCGCTTGGTGTTTAATCATTGCAGGGATGCCTCTCTGATTATTCACCCAGGTTTCAGAGGTGTCAGACCACGCAGGG
ACACCTGCCTTGGTCCTTCACCCTTAGTGGCAAGTCCCGCTTTTCTGGGGAAGGGGACCCACTAGAAGGCAGACTGCCCAGCTCGCCCGG
CAGCCACTCCTAGAGCCCCTAAAGCTCTAGCCCAAGGCTCTCTGACCGACTCCTTCTCAGATCTGCTCGGCTTAGCGACTGAAGATTGAC
GCTGCCCGATCACCTCGGAAGCCCCCCGGACCATCATGGACGCCAAGCTTCAGACTCAGCCCGCCTGCACCCAGGTGAAATAAACAGCCA
CGTTGCTCACACAAAGCCTGTTTGGTGGTCTCTTCACATGGACGCGCA
   Mouse
Figure 3 Conservation of SPINT5. The mouse and human SPINT5 transcripts were aligned with the computer program ALIGN. The nucleotide
sequences that correspond to exon 1-3 of mouse and human SPINT5 are shown with identities indicated by vertical bars and gapped
nucleotides by dashes. The second exon is shaded, with non-aligning nucleotides in the human gene inserted below; note the CAG at the end
of the insertion that might indicate splice acceptor site, and the arrow that indicates starting nucleotide of the shorter 5’ RACE product. The 3’
ends of mouse Spint5, human SPINT5, and alternative 3’ transcript of human SPINT5 are given at the bottom of the figure with poly-adenylation
signals written in bold; location of introns in the alternative SPINT5 3’ end are indicated with opposing arrows.
Table 2 PCR efficiency
Gene Ct value range Slope R
2 PCR efficiency
APRT 23-31 -3.14 0.996 2.08
CSTB 20-29 -3.35 0.996 1.99
SPINT3 20-29 -3.26 0.998 2.02
SPINT4 21-28 -3.48 0.997 1.94
The efficiency of PCR experiments was calculated by regression analysis of Ct
values generated by serial dilution of epididymis cDNA.
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Page 5 of 13concentrations of BSTI or BPTI (Figure 4A). A compari-
son with commercially available BPTI isolated from
bovine pancreas showed that the recombinant protein
inhibited chymotrypsin equally well (Figure 4B).
Experiments with SPINT3 and SPINT4 generated
recombinant proteins in yields that were similar to
those of BPTI and BSTI. Almost all recombinant
SPINT3 was in a monomeric form, whereas this was the
case for only a fraction of SPINT4 (Figure 5). Repeated
experiments to produce recombinant SPINT5 in the
same way failed and no recombinant protein could be
isolated with the Ni-chelate column.
Recombinant SPINT3 and SPINT4 were tested on a
panel of eight proteases with different specificity, in
order to identify target enzymes. The recombinant pro-
teins were tested at different molecular ratios of enzyme
and inhibitor, but none of them displayed inhibitory
activity towards the proteases in the panel at up to
1000-fold molar excess.
Discussion
In this report, we describe the transcripts of three novel
genes encoding Kunitz motif. They were discovered by
analysis of nucleotide sequences from a locus where we
previously have identified homologous genes of semen
coagulum proteins and putative WFDC-type serine pro-
t e a s ei n h i b i t o r s[ 1 4 ] .I ne a r l i e rs t u d i e sw eh a v es h o w n
that genes of different semen coagulum proteins and
WFDC-type protease inhibitors are homologous, in
spite of lacking structural similarity of their protein pro-
ducts [10-12,15]. By and large, these similarly organized
genes carry the signal peptide, the secreted protein and
3’ non-translated nucleotides on three separate exons.
Sequence and size conservation of the first and the
third exon suggests that the genes are homologous,
whereas the second exons, encoding the secreted pro-
tein, in most instances display very little sequence con-
servation. Two mechanisms, de novo selection of splice
sites and size expansion by duplication of repeats in
combination with replication slippage, have been pro-
posed to explain the structural variation of the second
exon [10].
Table 3 Tissue specific expression.
Relative transcript levels (%)
Gene used for normalization
Tissue Gene APRT s CSTB s
Breast SPINT3 0,010 0,001 0,018 0,002
SPINT4 0,006 0,002 0,010 0,004
Epididymis SPINT3 45 5 45 7
SPINT4 100 14 100 18
SPINT5 0,003 0,0005 0,003 0,0006
Kidney SPINT3 0,0006 0,0002 0,002 0,0004
SPINT4 0.006 0,002 0,016 0,002
Prostate SPINT3 0,0007 0,0005 0,001 0,0007
SPINT4 0,001 0,001 0,002 0,002
Seminal vesicle SPINT3 0,056 0,017 0,053 0,014
SPINT4 0,015 0,004 0,014 0,003
Skin SPINT3 0,029 0,007 0,053 0,013
SPINT4 0,003 0,001 0,005 0,002
Thyroid SPINT3 0,004 0,003 0,005 0,004
SPINT4 0,012 0,004 0,013 0,004
Testis SPINT3 No signal No signal No signal No signal
SPINT4 0,004 0,004 0,008 0,007
Transcript levels of putative Kunitz inhibitors in normal tissues were analyzed
by qRT-PCR. The transcript levels were calculated by the comparative ΔΔCt
method and normalized with the housekeeping genes APRT and CSTB.
Transcript levels are given as % of SPINT4 levels in the epididymis, which was
set to 100%. SPINT5 was only detected in the epididymis.
A
B
Figure 4 Protease inhibition with recombinant BPTI.( A )S e r i a l
dilutions of recombinant BPTI were incubated with 20 nM bovine
chymotrypsin (■), 50 nM human plasmin (▼), and 5 nM bovine
trypsin (▲). (B) Recombinant BPTI (filled symbols) and BPTI isolated
from bovine pancreas (open symbols) were incubated with 10 nM
(circles) and 20 nM (squares) bovine chymotrypsin. Residual
amidolytic activity was measured and compared with samples
without added inhibitor
Clauss et al. BMC Biochemistry 2011, 12:55
http://www.biomedcentral.com/1471-2091/12/55
Page 6 of 13The novel genes of putative Kunitz inhibitors are
organized in a similar way as the semen coagulum and
WFDC genes. Another characteristic feature of the
genes is that the splice acceptor of the second exon
always is that of a phase 1 exon, which means that it
starts with the second nucleotide of the codon. Of the
novel genes, it is only SPINT4 that has all of the com-
mon features, whereas SPINT3 is lacking the third exon
similar to WFDC10A and WFDC10B.A taf i r s tg l a n c e ,
human SPINT5 might appear to differ from the other
genes at the locus, as the structure of the longer 3’
RACE product suggests that it could be transcribed
from 8 exons. However, the splice form that is ortholo-
gous with mouse Spint5 is very similar organized as
SPINT4, except for the presence of the puzzling small
second exon. In spite of the lacking relationship between
the protein products, the similarities in gene organiza-
tion, chromosomal location, and site of expression, sug-
gests that the novel genes with Kunitz motif are
homologous with genes encoding WFDC-inhibitors and
semen coagulum proteins. A Kunitz inhibitor within the
frame of a WFDC gene could have evolved by exon
shuffling that created an intermediate encompassing
both a WFDC and a Kunitz domain, as is present in
SPINLW1 and WFDC6. A subsequent loss of the
WFDC domain in a purifying process would have
created a Kunitz gene with the same regulatory
sequences as the original WFDC gene.
The problems we experienced in generating a full-
length transcript of human SPINT5 were probably
caused by low levels of transcript in the samples from
our tissue panel. Furthermore, the in frame stop codon
between the signal peptide and the Kunitz motif could
indicate that the RACE products were emanating from
either a not fully spliced nuclear transcript or a erro-
neously spliced cytoplasmic transcript. In order to
address this, we generated the sequence of mouse
Spint5 a n dc o m p a r e di tw i t ht h o s eo ft h eh u m a nt r a n -
scripts. The failure to detect a mouse equivalent of the
alternative human SPINT5 transcripts and the peculiar
structure of them, with no coding information for a sig-
nal peptide or a 3’ non-translated sequence derived
from four exons, suggests that they could originate from
not fully processed messages or cryptic transcripts gen-
erated by accidental transcription of the gene in a tissue
where it is not normally expressed. The former could
also be the case for the human transcript that is ortho-
logous with the single mouse transcript, where the sec-
ond exon might not have been fully processed, as it
contains an in frame stop codon that prevents transla-
tion of the Kunitz motif. When the sequence of the sec-
ond exon was shortened to the corresponding nine
nucleotide of its mouse ortholog, the reading frame is
kept and a Kunitz domain is translated from the third
exon. The presence of an appropriately located CAG tri-
plet that could function as splice acceptor in exon 2
raises the possibility that human SPINT5 could be pro-
cessed the same way as mouse Spint5.
Semi-quantitative RT-PCR has previously shown that
several of the WFDC genes at the locus on chromosome
20 are expressed in many different tissues [14]. How-
ever, the same study also showed that a number of the
genes at the telomeric sublocus, e.g. WFDC8, WFDC9,
WFDC10A and WFDC13, are transcribed in the epididy-
mis with certain specificity. Epididymal specificity in
expression has also been reported for SPINLW1 and
WFDC2 [20,21]. In this study it is shown that SPINT3
and SPINT4 a r eh i g h l ys p e c i f i cf o rt h ee p i d i d y m i sa s
well. This conclusion is supported by qPCR that show
expression levels in the epididymis that are of the same
order of magnitude as for CSTB, a housekeeping gene
with low to moderately high expression levels. More
importantly, the transcript levels of SPINT3 and SPINT4
in the epididymis exceeds those of the same genes in
other tissues that were analyzed by more than three
orders of magnitude, which suggests that the expression
in those tissues might be neglectable. The result is also
in line with an earlier study aiming at identification of
epididymis-specific genes in the mouse, in which Spint4
was found to be highly expressed in a narrow segment
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Figure 5 SDS-PAGE. Purified recombinant proteins were separated
by SDS-PAGE and then silver stained. Masses of the molecular
standard proteins in kDa are given to the left.
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Page 7 of 13encompassing distal caput and proximal corpus of epidi-
dymis [22].
Transcripts of SPINT5 were only detected in the epi-
didymis, but at a level that is at least four orders of
magnitude lower than for SPINT3 and SPINT4.I na n a -
logy with the discussion above, the low transcript level
would indicate that under normal conditions SPINT5
presumably is of less importance in the tissues that were
analyzed in this study. From this follows that SPINT5
probably is expressed either at a relatively rare anatomi-
cal site or at a developmental stage that is not covered
by this investigation. In ruminants, it has been shown
that several proteins with Kunitz motifs are expressed
and secreted by the conceptus prior to, or at the time
of, trophoblast implantation [23,24]. Although, there are
major differences in the implantation process between
ruminants and many other mammals, e.g. in the timing,
it is not unlikely that Kunitz inhibitors could be
expressed at the time of trophoblast implantation also
in humans, and one interesting candidate to study
would be SPINT5.
Protein domains are building blocks that usually fold
to explicit three dimensional structures, which many
times have a specific function. The Kunitz domain con-
sists of 50-60 amino acid residues, six of which are Cys
that form three disulphide bonds and have characteristic
locations in the primary structure. Studies on recombi-
nant Kunitz domains expressed in E. coli show that
proper folding and disulphide formation can be achieved
either by directing the recombinant protein to the peri-
plasmic space or by refolding of the protein extracted
from inclusion bodies [17,25]. Our approach was to
express the recombinant protein as a part of a larger
fusion product with thioredoxin, that would generate
high solubility and support the proper folding of the
Kunitz domain, and by using the E. coli K-12 sub-strain
Origami(DE3), formation of disulphide bonds in the
cytoplasm would be favored. Studies with recombinant
BPTI and BSTI showed that the proteins isolated from
the cytoplasm were almost exclusively in a monomeric
state, which suggests correct disulphide formation and
folding of the Kunitz domain. Furthermore, the recom-
binant inhibitors were as functionally active as BPTI iso-
lated from bovine pancreas, something that also
indicates that they are correctly folded. Expression of
SPINT3 yielded an exclusively monomeric protein in a
similar way as BPTI and BSTI, which suggests that the
Kunitz domain was properly folded. Recombinant
expression of SPINT4 yields high molecular mass com-
plexes that probably consist of misfolded peptide chains
held together by disulphide bonds in an unorganized
way, but also a substantial fraction of monomers that
presumably are correctly folded. The structure of
SPINT4 differs from that of the consensus Kunitz
domain. The latter contains three conserved disulphide
bridges, but in SPINT4 there will only be two, as one
Cys is missing. The absent disulphide would have linked
the C-terminal alpha-helix to one of the beta-strands at
the core of the molecule. Earlier experiment has shown
that the folding of the Kunitz domain is only minimally
affected by removal of this bridge and would not affect
the protease-binding loop that is situated at the opposite
side of the molecule [26]. The location of a Cys amino-
terminal to the Kunitz domain in SPINT4 suggests that
the monomeric form will have either two free thiol
groups, or more likely a disulphide bridge between
them. The crystal structure of BPTI shows that the
amino-terminus of the protein is located relatively close
to the third Cys of the Kunitz motif. Therefore, it is not
unlikely that a disulfide bridge could be formed in
SPINT4 without affecting the protease-binding loop,
which is located at the other end of the molecule. This
would create a strand of 6 amino acid residues that
links the protein’s amino-terminal part to the third Cys
of the Kunitz motif.
Despite several attempts, we did not succeed to isolate
recombinant SPINT5 from the cytoplasm of Origami
(DE3) cells. It is not clear whether the failure was due
to inherent instability of the protein product or whether
the problems are due to technical problems with our
construct, but future studies will presumably give an
answer.
The experiments with recombinant BPTI demon-
strated, not only that the Kunitz domain can be cor-
rectly folded in Origami(DE3) cells, but also that the
fusion product with thioredoxin could be an equally effi-
cient protease inhibitor as BPTI isolated from a natural
source. It is therefore likely that recombinant SPINT3
and SPINT4 would be functional as well. They were
tested by a set of proteolytic enzymes that represent dif-
ferent catalytic specificities, but unfortunately, we did
not succeed to identify a target protease. The amino
acid residues in BPTI that interact with target proteases
have been characterized in detail and homologous resi-
dues can be identified in other Kunitz domains by
sequence alignment [27]. There are several residues that
are important for protease-binding, but those flanking
the scissile bond, particularly the residue at the P1 posi-
tion, are vital for the target- protease specificity [28,29].
The probable scissile bonds in SPINT3 and SPINT4 are
between Gln and Thr, and Tyr and Glu, respectively
(Figure 6). One might then have expected both of them
to inhibit PSA, which has been demonstrated to cleave
C-terminal to both Gln and Tyr in SEMG1 and SEMG2
[30]. There was no inhibition and perhaps the interac-
tion with the inhibitor protein was prevented by the kal-
likrein loop in PSA, which restricts the access to the
catalytic cleft [31]. In chymotrypsin there is no such
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Page 8 of 13structure as the kallikrein loop and SPINT4 could be
predicted to interact with this enzyme, which cleaves
after large hydrophobic residues. Under our experimen-
tal condition there was no inhibition, which suggests
that there is no high affinity interaction between chymo-
trypsin and SPINT4. This emphasizes the importance of
contact between amino acid residues other than those of
the scissile bond, which is nicely shown with the inhibi-
tion of chymotrypsin by BPTI; the scissile bond in this
case is between Lys and Ala, i.e. residues that would
predict specificity for trypsin, but not chymotrypsin. In
spite of this, chymotrypsin is inhibited by BPTI.
The WFDC genes at the locus on chromosome 20
could be important during sperm maturation, as several
of them are highly expressed in the epididymis. There is
this far no report on target proteases in the epididymis.
It has also been speculated that the WFDC genes are
important but not fully recognized components, of
innate immunity; in which some modulate host response
by regulating endogenous pro-inflammatory proteases,
such as elastase and cathepsin G, whereas others regu-
late poorly characterized exogenous proteases used for
tissue invasion by microbes [16]. The genes expressing
Kunitz domains could have a similar function. In this
report it is shown that SPINT3 and SPINT4 with high
specificity are expressed in the epididymis, which sug-
gests a role in the maturation of spermatozoa. An innate
immune function can also inferred, as it has been shown
that the Kunitz domain of SPINLW1 inhibits elastase
and display antibacterial activity [32].
Conclusions
We have in this report described three genes that pro-
duce small secreted proteins, composed of single Kunitz
domains that are relatively specific for the epididymis.
The similar organization, chromosomal location and site
of expression, suggests that the novel genes encoding
Kunitz motifs are homologous with the genes of
WFDC-type protease inhibitors and semen coagulum
proteins, in spite of lacking similarity in primary struc-
ture of their protein products. A likely mechanism, by
which the genes could have been formed, include an
exon shuffling event, in which the Kunitz motif was
taken up by a WFDC gene, and a following purifying
process, in which the WFDC domain was lost. This
would then be the third mechanism, beside de novo
selection of splice site and repeat expansion, by which
the regulatory frame of a conserved WFDC/semen coa-
gulum gene could generate a new protein product. The
restricted expression of the novel genes to the epididy-
mis suggests that the secreted Kunitz domains are
important in male reproduction. The recombinantly
produced proteins are presumably bioactive, as demon-
strated with similarly made BPTI, but may have a nar-
rower spectrum of inhibition, as indicated by the lacking
activity against eight proteases with differing specificity.
Another possibility is that they have lost the protease
inhibiting property, which is typical of Kunitz domains,
in favor of new hitherto unidentified functions.
Methods
Identification of novel genes in genomic DNA sequences
The nucleotide sequence oft h eW F D C - l o c u so nc h r o -
mosome 20 was translated in six reading frames and
scanned for short sequence motifs as previously
described [14]. Kunitz domains were localized using the
motif GCXGN and NNF (single letter amino acid code
where × means any residue) and confirmed by identifi-
cation of appropriately spaced Cys residues through
manual inspection of the sequence.
RT-PCR
Preparation of RNA samples and conditions for cDNA
synthesis has been described earlier [15]. Primers were
designed from nucleotide sequences originating from
different exons to enable differentiation between PCR
products from spliced transcripts and non-spliced tran-
scripts or genomic DNA (Table 4). A panel of cDNA
derived from different tissues were screened by PCR
using previously described conditions [14]. The PCR
products were analyzed by electrophoresis in 2% agarose
gels stained by ethidium bromide. Samples that by this
BPTI     ----AQRPDFCLEPPYTGPCKARMIRYFYNAKAGLCQPFVYGGCRAKRNNFKSSEDCMRTCGGAIGPW
SPINT4   --------DPCKLDMNFGSCYEVHFRYFYNRTSKRCETFVFSGCNGNLNNFKLKIEREVACVAKYKPP
SPINT5   --------EYCNYPLKKGTCNSYLTRFYYNTLTFLCEPFVFSGCGGNRNNFKQKYFCEKMCITEK---
SPINT3   DTIKDLLPNVCAFPMEKGPCQTYMTRWFFNFETGECELFAYGGCGGNSNNFLRKEKCEKFCKFT----
WFDC8    --------EPCMLPVRHGNCNHEAQRWHFDFKNYRCTPFKYRGCEGNANNFLNEDACRTACMLI----
SPINLW1  --------DVCEMPKETGPCLAYFLHWWYDKKDNTCSMFVYGGCQGNNNNFQSKANCLNTCKNK----
WFDC6    ------IYAVCHR--RLAPAWPPYHTGGTIKKTKICSEFIYGGSQGNNNNFQTEAICLVTCKKYH---
Figure 6 Conservation of the Kunitz domain. Exons encoding Kunitz domains were translated and the resulting peptide sequences were
aligned using CLUSTALW. The amino acid residues homologous with those of the peptidase binding loop (P3-P’3) in BPTI are framed and the
P1 position is shaded. Positions with mutated Cys in SPINT4 and WFDC6 are framed and shaded.
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Page 9 of 13procedure generated a PCR product from a spliced tran-
script were taken to quantitative PCR using real time
detection.
Quantitative RT-PCR (qRT-PCR)
The cDNA for qRT-PCR was made from DNAase-free
RNA using reagents and protocol provided by the sup-
plier (Fermentas, Helsingborg, Sweden). Briefly, 3 μgo f
RNA was treated at 37°C for 30 min with 1 unit of
RNase-free DNase in 10 μlo f1 0m MT r i s - H C lp H7 . 5 ,
2.5 mM MgCl2 and 0.1 mM CaCl2. Following addition
of 1 μl of 25 mM EDTA, the enzyme was inactivated by
incubation at 65°C for 10 min. The material was then
taken to oligo(dT)18-primed cDNA synthesis in a
volume of 20 μl using the RevertAid H Minus First
Strand cDNA Synthesis kit (Fermentas) for 1 h at 42°C.
Finally, the reverse transcriptase was inactivated by heat-
ing to 70°C for 5 min, and the samples were diluted
with H2Ot o2 0 0μl and stored at -20°C until used.
Negative controls were produced in the same way, but
with the reverse transcriptase omitted.
The PCR was done in MicroAmp Optical 384-Well
Reaction Plates (Applied Biosystems, Stockholm, Swe-
den) using the 7900 HT Fast Real-Time PCR System
(Applied Biosystems). PCR primers were selected such
that the resultant transcript should be less than 150 bp
(Table 4). The reaction mix was made from 3 μlo f
diluted cDNA, 2 μl of primers at 5 μM each, and 5 μlo f
Fast SYBR Green Master Mix (Applied Biosystems).
Samples were analyzed in quadruplicates. The cycling
conditions consisted of an initial activation step at 95°C
for 20 s, followed by 40 cycles of denaturation at 95°C
for 1 s and annealing and extension at 60°C for 20 s.
Following PCR the homogeneity of the products were
checked by DNA melting analysis. The real time PCR
data were analyzed by the Sequence Detection System
Table 4 Oligonucleotide primers.
Target gene Purpose Primer sequence (5’ to 3’)
Human SPINT3 RT-PCR and 3’ RACE CCTCTCTCTCGTTTCTCCTGATTCTCACT
Human SPINT3 RT-PCR and 5’ RACE CGCAGCCTCCGTAAGCAAATAACTCACAT
Human SPINT3 qRT-PCR TCAGGCCTCTCTCTCGTTTCTCCTGATT
Human SPINT3 qRT-PCR CCCTTTTCCATAGGAAAAGCGCATACAT
Human SPINT4 RT-PCR and 3’ RACE CATCTTCTGCTCATTGAATACCCTGTTATT
Human SPINT4 RT-PCR and 5’ RACE TTACAGCCGGAGAAGACAAAAGTTTCACAT
Human SPINT4 qRT-PCR TCTTCTGCTCATTGAATACCCTGTTATT
Human SPINT4 qRT-PCR GAACTTCATAGCAGCTTCCAAAATTCAT
Human SPINT5 3’ RACE CAACTATCCTCTGAAGAAGGGCACCTGT
Human SPINT5 Nested 3’ RACE ATGTGAGCCCTTTGTCTTCAGTGGCTGT
Human SPINT5 5’ RACE GTTTCTGTTGCCTCCACAGCCACTG
Human SPINT5 Nested 5’ RACE CAGCCACTGAAGACAAAGGGCTCAC
Human SPINT5 qRT-PCR GCTGTGGAGGCAACAGAAACAACTTTAA
Human SPINT5 qRT-PCR CCTCCTTCTGTCATATTAAGGCCCTATT
Mouse Spint5 RT-PCR and 3’ RACE CCTGCAGGAGTCCGAAGTCAACTCTGCGA
Mouse Spint5 RT-PCR and 5’ RACE TGCAACGGACTTCACAGAGGTATTTAGT
Human APRT qRT-PCR CTTGGACTGGGCTGCGTGCTCATCCGAA
Human APRT qRT-PCR GTCCTGGCTCCAGGGCGTCTTTCTGAAT
Human CSTB qRT-PCR AGTTCCCTGTGTTTAAGGCCGTGTCATT
Human CSTB qRT-PCR GTTTTCATGAGGGAGAGATTGGAACACT
Human SPINT3 Cloning in pET32b GGATCCGAATTCGCGAGACACTATCAAGGATCTCCTCCCAAAT
Human SPINT3 Cloning in pET32b TCGAGTGCGGCCGCTCAGGTGAACTTGCAGAATTTCTCACAT
Human SPINT4 Cloning in pET32b CGAATTCGGGTGGTGTTAATAAAATTGCGGAGA
Human SPINT4 Cloning in pET32b GCGCGGCCGCCTATTGACTTTGGTCCTTTTCAG
Human SPINT5 Cloning in pET32b CAGTGAATTCCGAATACTGCAACTATCCTCTGAAGAA
Human SPINT5 Cloning in pET32b TGCAGCGGCCGCTACTTTTCAGTAATACACATTTTTTCACAGA
Bovine BPTI Cloning in pET32b GGATCCGAATTCGCCTGACTTCTGCCTAGAGCCTCCATAT
Bovine BPTI Cloning in pET32b TCGAGTGCGGCCGCTCACCAGGGCCCAATAGCACCACCACAGGT
The underlined sequences are not present in the target genes.
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Page 10 of 132.3 software. The relative amount of transcripts was cal-
culated by the comparative ΔΔCt method and normal-
ized with values of the housekeeping genes CSTB and
APRT [33,34]. The PCR efficiency was calculated from
Ct values generated by serially diluted epididymis
cDNA.
Rapid amplification of cDNA ends (RACE)
Synthesis of RACE ready cDNA and touch down PCR
was done with the SMART or the SMARTer RACE
cDNA Amplification Kits (Clontech, In vitro, Stockholm,
Sweden) and RNA from human epididymis or mouse
testis, essentially as described [14]. The primers were
the same as used for RT-PCR, except for experiment on
human SPINT5, in which RACE products were gener-
ated with the SMARTer RACE cDNA amplification kit
and two rounds of PCR using nested primers, as recom-
mended in the protocol supplied with the kit. The
RACE products were purified using JetQuick (Genomed,
Saween Werner AB, Malmö, Sweden) or Nucleotrap
(Clontech) and subjected to DNA sequencing using the
Big Dye Terminator Cycle Sequencing Ready Reaction
Kit 3.0 and a 3730 DNA Analyzer (Applied Biosystems).
The sequences were analyzed with the Sequence Analy-
sis 5.1 program (Applied Biosystems) and bioinformatics
tools available at the EBI web server (http://www.ebi.ac.
uk/Tools/). Translations of transcripts were screened for
signal peptides using the SignalP 3.0 server [35].
Sequences were deposited with the Genbank Sequence
Database and are available under accession numbers
AY372172, AY372173, AY372174, and AY542490.
Construction of expression plasmids
Transcripts for expression of Kunitz domains in the
prokaryotic expression vector pET32b were generated
by PCR using primers that contain restriction enzyme
recognition sites for EcoRI and NotI (Table 4). The PCR
protocol was the same as for RT-PCR and as template
served human epididymal cDNA, and human and
bovine genomic DNA. The PCR that was run in order
to generate the control plasmid encoding BPTI also
yielded transcript for the homologous bovine spleen
trypsin inhibitor (BSTI) [36]. The restricted PCR pro-
ducts were ligated into plasmids using the Rapid DNA
Ligation Kit (Fermentas) and different chemo-competent
bacteria were transformed and grown with appropriate
antibiotics. Plasmids were purified by QIAprep Spin
MiniPrep Kit (Qiagen AB, Sollentuna, Sweden) from 1.5
ml of overnight cultures grown in LB medium contain-
ing appropriate antibiotics, and then digested with
restriction enzyme and analyzed by electrophoresis in
2% agarose gels containing ethidium bromide (1 μg/ml).
Plasmids containing inserts of correct size were verified
by DNA sequencing.
Protein expression
Origami(DE3) bacteria containing plasmids designed for
prokaryotic expression were grown at 37°C in 500 ml of
LB medium containing antibiotics until mid-logarithmic
phase. The culture was chilled and the synthesis of
recombinant protein was induced by addition of isopro-
pyl-b-D-thiogalactopyranoside (IPTG) to a final concen-
tration of 1 mM, where after growth continued at 30°C
for 5 hours. Bacteria were harvested by centrifugation at
10,000 × g for 10 minutes at 4°C. The resulting pellet
w a sw a s h e di n5 0m lo f2 0m MT r i s - H C l ,0 . 5MN a C l ,
pH 7.5 and then resuspended in the same buffer con-
taining 1 mg/ml of lysozyme. The suspension was made
1 mM with respect to PMSF and then incubated on ice
for 30 min. Next, the bacterial suspension was sonicated
with an Ultrasonic processor XL 2020 (Misonix inc.,
Farmingdale, NY, USA) for 30 minutes with 10 s burst
separated by intervals of 10 s, using the power setting 3.
Cell debris was removed by centrifugation at 16,000 × g
for 20 min. The supernatant was dialyzed against 50
mM Na-phosphate pH 8.0, 0.3 M NaCl and then passed
through a 0.45 micron filter (Millipore AB, Solna,
Sweden).
The recombinant proteins were purified on a 12 ml
column of Ni-NTA superflow (Qiagen) that was run at
2 ml/min in 50 mM Na-phosphate, 0.3 M NaCl and 10
mM imidazole, pH 8.0. Proteins were eluted by increas-
ing the concentration of imidazole to 100 mM or 300
mM.
Protease inhibition
The amidolytic activity of proteases was measured with
purified enzymes and synthetic peptide substrate. The
assays were run in microtiter plates with enzyme, inhibi-
tor and peptide substrate in wells containing 100 μlo f
50 mM Tris-HCl, pH 8.0, 0.15 M NaCl and 0.05%
Tween 20. Enzymatic activity was measured at 37°C in a
Viktor
2 instrument (Wallac, Upplands Väsby, Sweden)
and displayed as the time-dependent increase in absor-
bance at 405 nm. Inhibitors at various concentrations
were incubated with proteases for 15 min at 37°C in the
assay buffer. Reactions were initiated by addition of pep-
tide substrate. The following concentrations of proteases
(purchased from Sigma-Aldrich Sweden AB, Stockholm,
Sweden) were used: 5 nM of bovine trypsin, 10 and 20
nM of bovine chymotrypsin, 50 nM human plasmin, 10
nM human urokinase, 15 nM bovine thrombin, 15 nM
bovine Factor Xa, 10 nm human leukocyte elastase, and
20 nM porcine pancreatic elastase. Analysis was also
made with 10 nM human prostate-specific antigen
(PSA), purified from human s e m i n a lp l a s m ab ya f f i n i t y
chromatography using Mab 2E9 [37]. The activity of
trypsin, plasmin, urokinase, thrombin and Factor Xa
were measured with the peptide substrates S-2366,
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Page 11 of 13pyroGlu-Pro-Arg-pNA (Chromogenix, Mölndal, Swe-
den), chymotryptic activity with S-2586, MeO-Suc-Arg-
Pro-Tyr-pNA (Chromogenix,), elastase activity with N-
Suc-Ala-Ala-Ala-pNA (VWR International AB, Stock-
holm, Sweden) and, PSA activity with Mu-Ser-Ser-Tyr-
Tyr-AMC (custom made by MedProbe, Lund, Sweden).
The inhibition was calculated as the decrease in enzy-
matic activity between samples pre-incubated with inhi-
bitor and buffer only. The kinetic data was analyzed and
displayed using the computer program GraphPad Prism,
version 4.00 for Windows (GraphPad Software, San
Diego CA, USA)
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